Global Anti-D Immunoglobulin Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Intramuscular Anti-D Immunoglobulin, and Intravenous Anti-D Immunoglobulin), By Application (Hemolytic Disease of the Newborn (HDN), Rh Immunoprophylaxis During Pregnancy, and Management of Thrombocytopenic Patients), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035.

Global Anti-D Immunoglobulin Market Insights Forecasts to 2035

• The Global Anti-D Immunoglobulin Market Size Was Estimated at USD 3.20 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.46% from 2025 to 2035
• The Worldwide Anti-D Immunoglobulin Market Size is Expected to Reach USD 5.74 Billion by 2035
• Asia Pacific is expected to grow the fastest during the forecast period.

The global anti-D immunoglobulin market size was worth around USD 3.20 billion in 2024 and is predicted to grow to around USD 5.74 billion by 2035 with a compound annual growth rate (CAGR) of 5.46% from 2025 and 2035. Increased prenatal screening, growing maternal health initiatives, technological advancements in plasma therapy, and rising demand in emerging nations with better healthcare infrastructure and awareness present opportunities for the anti-D immunoglobulin market.  

Market Overview

The global industry centered on the manufacturing, marketing, and use of anti-D immunoglobulin products, which are made from human plasma and are intended to prevent Rh sensitization in Rh-negative people, especially pregnant women, is referred to as the anti-D immunoglobulin market. This market serves clinical environments, including hospitals and maternity clinics, and includes a variety of formulations, including intramuscular and intravenous varieties. Recombinant technologies and customized diagnostics present the anti-D immunoglobulin market's main opportunities for the future. 

Government-sponsored immunization programs, expanding need for preventative therapy for infant hemolytic illness, and growing awareness of Rh incompatibility are all driving the market's rapid growth. The market for anti-D immunoglobulin is being driven by the expansion of maternity care centers, clinics, and hospitals, especially in developing nations, which improve access to anti-D immunoglobulin products and the infrastructure needed to administer them.  

Report Coverage

This research report categorizes the anti-D immunoglobulin market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the anti-D immunoglobulin market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the anti-D immunoglobulin market. 

Driving Factors

Governments and healthcare providers are becoming active in procurement as a result of market pressure brought on by the current clinical scenario. Manufacturers are stabilizing their supply chains by investing in improved manufacturing scale-ups at the same time, which is driving the anti-D immunoglobulin market expansion. The market for anti-D immunoglobulin, which is a crucial sector of the larger pharmaceutical industry, is mostly concentrated on treating different blood-related conditions and preventing pregnant women from receiving the Rh vaccine. The market for anti-D immunoglobulin is expanding due to a number of important factors.

Restraining Factors

High manufacturing costs, a restricted supply of plasma, strict regulations, and unequal access worldwide, especially in low-income areas, are primary obstacles to widespread adoption and restricts the anti-D immunoglobulin market.  

Market Segmentation

The anti-D immunoglobulin market share is classified into product type and application.

• The intravenous anti-D immunoglobulin segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the product type, the anti-D immunoglobulin market is divided into intramuscular anti-D immunoglobulin and intravenous anti-D immunoglobulin. Among these, The intravenous anti-D immunoglobulin segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. The reason for the broad popularity of the intravenous anti-D immunoglobulin segment is its rapid action and ease of absorption. It is usually used to treat acute cases of immune thrombocytopenia and Rh incompatibility in a hospital environment.  

• The Rh immunoprophylaxis during pregnancy segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the anti-D immunoglobulin market is divided into hemolytic disease of the newborn (HDN), Rh immunoprophylaxis during pregnancy, and management of thrombocytopenic patients. Among these, the Rh immunoprophylaxis during pregnancy segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The widespread use of preventive programs aimed at Rh-negative women is responsible for the prevalence of Rh immunoprophylaxis during pregnancy, particularly in developed nations where routine administration at 28 weeks gestation and postpartum is common practice.

Regional Segment Analysis of the Anti-D Immunoglobulin Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the anti-D immunoglobulin market over the predicted timeframe.

North America is anticipated to hold the largest share of the anti-D immunoglobulin market over the predicted timeframe. The North American region has a high number of pregnant women need anti-D immunoglobulin due to the region's higher birth rates. The strong health system, widespread knowledge of Rh incompatibility, and government support for vaccination programs all add to the region's supremacy. The goal of North America's early screening protocols and prompt Rh immunoprophylaxis during pregnancy is to lower the incidence of hemolytic disease of the newborn (HDN). In the North American market, the United States is a significant player.

Asia Pacific is expected to grow at a rapid CAGR in the anti-D immunoglobulin market during the forecast period. The increased birth rates and rising number of Rh-negative women are the main causes of the anti-D immunoglobulin market in the Asia Pacific. The increased demand for anti-D immunoglobulin is a result of improved maternal healthcare systems and growing knowledge of Rh incompatibility. Rh screening systems are continuously being improved in nations like China, India, and the Philippines as part of public health policies because they think it could lower avoidable neonatal difficulties.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the anti-D immunoglobulin market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Grifols
• Bayer
• CSL Behring
• Saol Therapeutics
• Octapharma
• Kedrion Biopharma
• Emergent BioSolutions
• Bio Products Laboratory
• Kamada Pharmaceuticals
• Others  

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In August 2024, the UK & Ireland Blood Transfusion Network (UKIBTN) launched a new patient guide on the use of anti-D immunoglobulin during pregnancy to promote more knowledge, well-informed choices, and uniform recommendations throughout maternity services.  

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the anti-D immunoglobulin market based on the below-mentioned segments:  

Global Anti-D Immunoglobulin Market, By Product Type

• Intramuscular Anti-D Immunoglobulin
• Intravenous Anti-D Immunoglobulin

Global Anti-D Immunoglobulin Market, By Application  

• Hemolytic Disease of the Newborn (HDN)
• Rh Immunoprophylaxis during Pregnancy
• Management of Thrombocytopenic Patients

Global Anti-D Immunoglobulin Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa